Headlines about Chemed (NYSE:CHE) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chemed earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.1430786508601 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Chemed (NYSE:CHE) traded down $1.95 during midday trading on Friday, hitting $262.16. The company’s stock had a trading volume of 97,510 shares, compared to its average volume of 82,475. The company has a market capitalization of $4,216.78, a PE ratio of 58.26, a P/E/G ratio of 2.96 and a beta of 1.16. Chemed has a 52 week low of $163.50 and a 52 week high of $266.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.73 earnings per share. sell-side analysts predict that Chemed will post 4.73 earnings per share for the current year.

A number of equities research analysts have weighed in on the company. ValuEngine downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research report on Thursday, November 2nd. Royal Bank of Canada upped their target price on Chemed to $232.00 and gave the stock a “sector perform” rating in a research report on Tuesday, October 31st. TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Finally, Oppenheimer upped their target price on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Chemed has a consensus rating of “Hold” and a consensus target price of $236.00.

In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $250.00, for a total value of $250,000.00. Following the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Patrick Williams sold 11,000 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total value of $2,654,080.00. Following the completion of the transaction, the insider now directly owns 74,857 shares in the company, valued at approximately $18,061,496.96. The disclosure for this sale can be found here. Insiders sold 45,679 shares of company stock worth $10,628,959 in the last ninety days. 4.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/chemed-che-getting-somewhat-favorable-press-coverage-analysis-finds/1806298.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with Analyst Ratings Network's FREE daily email newsletter.